Cargando…

Active surveillance of carbapenem-resistant gram-negative bacteria to guide antibiotic therapy: a single-center prospective observational study

BACKGROUND: Carbapenem-resistant gram-negative bacteria (CRGNB) have become a public health concern worldwide. The risk factors associated with CRGNB infection after colonization are unknown, nor is the optimal timing of antibiotic treatment, warranting further investigation. METHODS: A 4-year singl...

Descripción completa

Detalles Bibliográficos
Autores principales: Liang, Qiqiang, Chen, Juan, Xu, Yongshan, Chen, Yibing, Huang, Man
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9215019/
https://www.ncbi.nlm.nih.gov/pubmed/35733230
http://dx.doi.org/10.1186/s13756-022-01103-0
_version_ 1784731125664448512
author Liang, Qiqiang
Chen, Juan
Xu, Yongshan
Chen, Yibing
Huang, Man
author_facet Liang, Qiqiang
Chen, Juan
Xu, Yongshan
Chen, Yibing
Huang, Man
author_sort Liang, Qiqiang
collection PubMed
description BACKGROUND: Carbapenem-resistant gram-negative bacteria (CRGNB) have become a public health concern worldwide. The risk factors associated with CRGNB infection after colonization are unknown, nor is the optimal timing of antibiotic treatment, warranting further investigation. METHODS: A 4-year single-center prospective observational study was conducted. CRGNB-colonized patients were incorporated on admission into our observation cohort for an active surveillance culture program, and analysis of risk factors associated with infections after CRGNB colonization was performed. We divided patients into empirical antibiotic therapy groups and standard antibiotic therapy groups according to whether antibiotics were used before or after cultures yielded a result to explore the relationship between the timing of antibiotics and clinical efficacy. RESULTS: 152 out of 451 CRGNB-colonized patients in the prospective observational cohort developed CRGNB infection. The risk factors associated with CRGNB infection after colonization included CRKP (P < 0.001, OR = 3.27) and CRPA (P < 0.001, OR = 2.97) colonization, history of carbapenems use (P < 0.001, OR = 5.48), and immunocompromise (P < 0.001, OR = 7.07). There were 88 infected patients in the empirical antibiotic therapy groups and 64 in standard antibiotic therapy groups. The mortality was lower in empirical therapy groups than standard therapy groups (17.0% vs. 37.5%, P = 0.004, OR = 0.32). CONCLUSIONS: CRGNB colonized patients who are prone to infection have some high-risk factors included CRKP and CRPA colonization, immunocompromise, and prior carbapenems use. Once infection occurs in CRGNB-colonized patients, early use of effective antibiotics may be associated with reduced mortality, but more studies are needed.
format Online
Article
Text
id pubmed-9215019
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-92150192022-06-23 Active surveillance of carbapenem-resistant gram-negative bacteria to guide antibiotic therapy: a single-center prospective observational study Liang, Qiqiang Chen, Juan Xu, Yongshan Chen, Yibing Huang, Man Antimicrob Resist Infect Control Research BACKGROUND: Carbapenem-resistant gram-negative bacteria (CRGNB) have become a public health concern worldwide. The risk factors associated with CRGNB infection after colonization are unknown, nor is the optimal timing of antibiotic treatment, warranting further investigation. METHODS: A 4-year single-center prospective observational study was conducted. CRGNB-colonized patients were incorporated on admission into our observation cohort for an active surveillance culture program, and analysis of risk factors associated with infections after CRGNB colonization was performed. We divided patients into empirical antibiotic therapy groups and standard antibiotic therapy groups according to whether antibiotics were used before or after cultures yielded a result to explore the relationship between the timing of antibiotics and clinical efficacy. RESULTS: 152 out of 451 CRGNB-colonized patients in the prospective observational cohort developed CRGNB infection. The risk factors associated with CRGNB infection after colonization included CRKP (P < 0.001, OR = 3.27) and CRPA (P < 0.001, OR = 2.97) colonization, history of carbapenems use (P < 0.001, OR = 5.48), and immunocompromise (P < 0.001, OR = 7.07). There were 88 infected patients in the empirical antibiotic therapy groups and 64 in standard antibiotic therapy groups. The mortality was lower in empirical therapy groups than standard therapy groups (17.0% vs. 37.5%, P = 0.004, OR = 0.32). CONCLUSIONS: CRGNB colonized patients who are prone to infection have some high-risk factors included CRKP and CRPA colonization, immunocompromise, and prior carbapenems use. Once infection occurs in CRGNB-colonized patients, early use of effective antibiotics may be associated with reduced mortality, but more studies are needed. BioMed Central 2022-06-22 /pmc/articles/PMC9215019/ /pubmed/35733230 http://dx.doi.org/10.1186/s13756-022-01103-0 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Liang, Qiqiang
Chen, Juan
Xu, Yongshan
Chen, Yibing
Huang, Man
Active surveillance of carbapenem-resistant gram-negative bacteria to guide antibiotic therapy: a single-center prospective observational study
title Active surveillance of carbapenem-resistant gram-negative bacteria to guide antibiotic therapy: a single-center prospective observational study
title_full Active surveillance of carbapenem-resistant gram-negative bacteria to guide antibiotic therapy: a single-center prospective observational study
title_fullStr Active surveillance of carbapenem-resistant gram-negative bacteria to guide antibiotic therapy: a single-center prospective observational study
title_full_unstemmed Active surveillance of carbapenem-resistant gram-negative bacteria to guide antibiotic therapy: a single-center prospective observational study
title_short Active surveillance of carbapenem-resistant gram-negative bacteria to guide antibiotic therapy: a single-center prospective observational study
title_sort active surveillance of carbapenem-resistant gram-negative bacteria to guide antibiotic therapy: a single-center prospective observational study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9215019/
https://www.ncbi.nlm.nih.gov/pubmed/35733230
http://dx.doi.org/10.1186/s13756-022-01103-0
work_keys_str_mv AT liangqiqiang activesurveillanceofcarbapenemresistantgramnegativebacteriatoguideantibiotictherapyasinglecenterprospectiveobservationalstudy
AT chenjuan activesurveillanceofcarbapenemresistantgramnegativebacteriatoguideantibiotictherapyasinglecenterprospectiveobservationalstudy
AT xuyongshan activesurveillanceofcarbapenemresistantgramnegativebacteriatoguideantibiotictherapyasinglecenterprospectiveobservationalstudy
AT chenyibing activesurveillanceofcarbapenemresistantgramnegativebacteriatoguideantibiotictherapyasinglecenterprospectiveobservationalstudy
AT huangman activesurveillanceofcarbapenemresistantgramnegativebacteriatoguideantibiotictherapyasinglecenterprospectiveobservationalstudy